Zangardi ML, Spring LM, Nagayama A, Bardia A (2019) Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?. Expert Opin Investig Drugs 28(2):107-112. doi: 10.1080/13543784.2019.1555239 PMID: 30507322
Summary: This publication explores the potential of sacituzumab as a treatment for triple-negative breast cancer, highlighting its promising role as a leading candidate for future therapeutic approaches. The study suggests that sacituzumab may represent a breakthrough in the management of this aggressive breast cancer subtype, raising hopes for improved outcomes in patients.